MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel. Show more
Location: 42 Hayarkon Street, Yavne, 8122745, Israel | Website: https://www.mediwound.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
221.1M
52 Wk Range
$14.14 - $22.50
Previous Close
$20.05
Open
$20.24
Volume
77,898
Day Range
$20.10 - $21.03
Enterprise Value
177.3M
Cash
38.27M
Avg Qtr Burn
-3.282M
Insider Ownership
17.97%
Institutional Own.
43.50%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
NexoBrid Details Eschar removal, Thermal burns | Approved Quarterly sales | |
EscharEx Details Venous Leg Ulcers | Phase 3 Data readout | |
MW005 Details Basal cell carcinoma, Cancer, Non-melanoma skin cancer, Skin cancer | Phase 1/2 Update |